Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).
Leukemia, Myeloid, Acute
DRUG: Cusatuzumab|DRUG: Azacitidine|DRUG: Venetoclax
Frequency and Severity of Adverse Events (AEs), Laboratory Abnormalities, and Physical Exam Findings as a Measure of Safety, Frequency and severity of AEs, laboratory abnormalities, and physical exam findings will be reported., Up to 42 months
Serum Concentration of Cusatuzumab, Serum concentration of cusatuzumab will be assessed., Up to 23 months|Number of Participants with Anti-cusatuzumab Antibodies, Number of participants with anti-drug antibodies to cusatuzumab will be reported., Up to 23 months|Percentage of Participants with Complete Response (CR), Percentage of participants with complete response based on European Leukemia Network (ELN) 2017 response criteria assessment will be reported., Up to 42 months|Percentage of Participants with Complete Remission with Partial Hematological Recovery (CRh), Percentage of participants with CRh will be reported based on ELN 2017 response criteria assessment., Up to 42 months|Percentage of Participants with CR with Incomplete Recovery (CRi), Percentage of participants with CRi will be reported based on ELN 2017 response criteria assessment., Up to 42 months|Percentage of Participants with CR plus CRh, Percentage of participants with CR plus CRh will be reported based on ELN 2017 response criteria assessment., Up to 42 months|Overall Response Rate (ORR), ORR is defined as percentage of participants with CR, CRh and CRi based on ELN 2017 response criteria assessment., Up to 42 months|Percentage of Participants with CR without MRD, Percentage of participants with CR without minimal residual disease (MRD) will be reported and is defined as less than (\<) 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level \<10\^-3)., Up to 42 months|Percentage of Participants with Negative MRD who Achieved CR, CRh, CRi, or Morphologic Leukemia-free State (MLFS), Percentage of participants with negative MRD who achieved CR, CRh, CRi, or MLFS will be reported and is defined as \< 1 blast or leukemic stem cell in 1,000 leukocytes (MRD level \<10\^-3)., Up to 42 months|Cohort 2 and 3: Time to Response, Time to response is defined as time from first dose to achieving the first response of CR, CRh, or CRi., Up to 42 months|Cohort 2 and 3: Duration of Response, Duration of response is defined as time from achieving the first response of CR, CRh, or CRi to hematologic relapse or death of any cause., Up to 42 months|Cohort 2 and 3: Red Blood Cell (RBC) or Platelet Transfusion Independence, Transfusion independence (RBC or platelets) is defined as a period of greater than or equal to (\>=) 56 consecutive days with no transfusion between first dose of study drug and the last dose of study drug +30 days., Up to 42 months
The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).